MOTS-c Peptide: Mitochondrial Signaling and Metabolic

Learn how MOTS-c, a unique mitochondrial signaling peptide, is reshaping research into cellular energy, metabolic flexibility, exercise response, and healthy aging. Scientists are exploring how it helps cells adapt to changing energy demands and maintain metabolic balance.

What Is MOTS-c?

MOTS-c is a 16-amino-acid mitochondrial-derived peptide described in scientific research on cellular metabolism and stress responses. Mitochondria are best known for their role in cellular energy production, but they also participate in signaling between cells and tissues.

Why Are Mitochondrial Peptides Important?

Mitochondria do more than produce cellular energy—they also communicate with the rest of the cell. Mitochondrial-derived peptides may act as stress-response signals that influence metabolism, cellular adaptation, and communication between mitochondria and the nucleus. Researchers are investigating their potential roles in metabolic flexibility, glucose regulation, insulin-sensitivity signaling, cellular responses to energetic stress, skeletal muscle and exercise adaptation, and the biology of healthy aging.

How Might MOTS-c Work?

Preclinical research suggests that MOTS-c may influence AMP-activated protein kinase (AMPK), a cellular energy-sensing pathway. It has also been studied in relation to glucose metabolism, insulin sensitivity, oxidative stress, skeletal muscle adaptation, and metabolic flexibility. These mechanisms remain under active investigation.

Areas of Research

Current MOTS-c Research

  • Metabolic Health and Insulin Sensitivity

    Animal and laboratory studies have examined whether MOTS-c may influence glucose utilization and insulin sensitivity. A Phase 2a clinical trial registered in 2026 is evaluating investigational MOTS-c in adults with prediabetes and overweight or obesity. Results have not yet been posted.

    View Clinical Trial
  • Exercise and Skeletal Muscle

    MOTS-c has been associated with exercise-related signaling and skeletal muscle metabolism. Human observational studies have measured changes in circulating mitochondrial-derived peptides after exercise, but this does not establish that administering MOTS-c reproduces the benefits of physical activity.

  • Healthy Aging Research

    Because mitochondrial function changes with age and chronic disease, researchers are studying MOTS-c as a potential marker and signaling molecule involved in age-related metabolic adaptation. Claims that MOTS-c reverses aging are not supported by established clinical evidence.

Current Evidence

Much of the frequently cited evidence comes from cell and animal studies. FDA’s 2026 briefing materials described a lack of clinical and nonclinical information adequate to support nominated compounded uses and noted the absence of human drug-product exposure data. Clinical benefits, dosing, treatment duration and long-term risks therefore remain uncertain.
Researcher presenting holographic mitochondrion labeled MOTS-C peptide

Possible Risks and Safety Concerns

The human safety profile of MOTS-c remains incomplete, particularly with repeated or long-term use. FDA has raised concerns about possible immune reactions, peptide aggregation and impurities, product consistency, and limited human exposure and safety data for compounded MOTS-c products.

Potential risks may include pain, redness, swelling, or bruising at the injection site; allergic or immune reactions; infection; contamination; dosing variability; and unintended changes in blood glucose or other metabolic markers. Medication interactions and risks during pregnancy, breastfeeding, cancer, autoimmune disease, or significant kidney or liver disease have not been adequately established.

Frequently Asked Questions

MOTS-c is a mitochondrial-derived peptide consisting of 16 amino acids. It has been studied as a signaling molecule in metabolism and cellular stress research.
Mitochondria generate cellular energy and also participate in signaling, stress responses and metabolic regulation. Research on mitochondrial peptides explores how these signals may affect whole-body physiology.
Those benefits have not been established for a MOTS-c drug product in rigorous human clinical trials. Preclinical findings should not be presented as proven patient outcomes.
No. MOTS-c is not an FDA-approved drug. FDA has reported insufficient information to know whether drug products containing MOTS-c would cause harm in humans.
Rules can change and depend on the governing organization. Athletes should check the current WADA Prohibited List and obtain advice from an authorized anti-doping or sports-medicine professional before use.
The human safety profile is not adequately established. Potential concerns include immune reactions, impurities, incorrect strength, contamination and unknown interactions.
Symptoms such as fatigue, weight change or poor glucose control require evaluation for common causes. Depending on the situation, testing may include glucose and HbA1c, blood count, metabolic panel, thyroid testing, medication review and other clinician-selected studies.
Interactions with diabetes, weight-loss, hormone and other medications have not been adequately characterized. Combining therapies can change glucose, blood pressure and other risks and should not be assumed safe.

schedule a Consultation

If you have concerns about metabolic health, weight, blood glucose, fatigue, or bone health, schedule a comprehensive medical evaluation. Evidence-based testing can help identify underlying factors and guide a personalized treatment plan using appropriate, clinically established options.

Selected References

The following clinical, regulatory, and peer-reviewed sources provide additional information about ongoing MOTS-c research, mitochondrial signaling, metabolic health, and exercise physiology.

Clinical Research
  • ClinicalTrials.gov. NCT07505745.
    MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (MOTS-MET).
    Phase 2a investigational study record.
    View study record
FDA and Regulatory Information
  • U.S. Food and Drug Administration.
    Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.
    Includes FDA’s discussion of potential immunogenicity, peptide-related impurities, product characterization, and limited human safety information concerning MOTS-c.
    View FDA information
  • U.S. Food and Drug Administration.
    FDA Evaluation of MOTS-c–Related Bulk Drug Substances: MOTS-c Free Base and MOTS-c Acetate.
    Pharmacy Compounding Advisory Committee briefing materials, July 23–24, 2026.
    View FDA briefing document
Metabolic and Cellular Signaling
  • Lee C, et al.
    The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
    Cell Metabolism. 2015;21(3):443–454.
    View on PubMed
  • Kim KH, et al.
    The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress.
    Cell Metabolism. 2018;28(3):516–524.e7.
    View on PubMed
Exercise and Skeletal Muscle Research
  • Reynolds JC, et al.
    MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
    Nature Communications. 2021;12:470.
    View on PubMed
  • Woodhead JST, Merry TL.
    Mitochondrial-derived peptides and exercise.
    Biochimica et Biophysica Acta—General Subjects. 2021;1865(12):130011.
    View on PubMed
Evidence context: The registered Phase 2a trial does not yet provide clinical results. Much of the remaining MOTS-c literature consists of laboratory, animal, observational, or review research.

Medical and Regulatory Disclaimer

MOTS-c is investigational and is not FDA approved to diagnose, treat, cure, or prevent disease. Information on this page is educational and should not be interpreted as evidence that MOTS-c is safe or effective. Compounded medications are not FDA approved, and their quality, safety, and effectiveness are not reviewed by FDA before marketing.